Drug Trial Radar · NCT05638854
A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Dec 8, 2022
Primary completion
Feb 16, 2026
Study completion Feb 16, 2026
Sponsor
- Lead sponsor
- Zenas BioPharma (USA), LLCIndustry
- Sponsor type
- Industry
- First posted
- Dec 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This double-blind, randomized, placebo-controlled study will assess the safety and pharmacokinetics of ZB002 in healthy participants and in participants with rheumatoid arthritis (RA). The study consists of 2 parts. Part A: Single Ascending Dose (SAD), which will include only healthy volunteers. Part B: Multiple Ascending Dose (MAD), will commence after completion of the SAD study and will include RA participants.
Conditions
- Healthy Volunteers
- Rheumatoid Arthritis
Interventions
ZB002Drug
ZB002 will be administered subcutaneously as per schedule specified in the respective arm.
PlaceboDrug
Placebo will be administered subcutaneously as per schedule specified in the respective arm.
ZB002Drug
ZB002 will be administered subcutaneously as per schedule specified in the respective arm.
PlaceboDrug
Placebo will be administered subcutaneously as per schedule specified in the respective arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety and Tolerability in HVsTime frame: Day 1 through Day 120
- Part B: Safety and Tolerability of multiple doses of ZB002 in participants with RATime frame: Day 1 through Day 176
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Veritus Research
Melbourne, Australia
NZCR New Zealand Clinical Research
Christchurch, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.